Featured Research

from universities, journals, and other organizations

Improved outcomes following kidney transplantation

Date:
March 1, 2011
Source:
Charité - Universitätsmedizin Berlin
Summary:
Researchers successfully tested a new therapeutic strategy that allows for superior renal function after kidney transplantation.

Universitätsmedizin Berlin, together with 16 other transplant centers in Germany and Switzerland successfully tested a new therapeutic strategy that allows for superior renal function after kidney transplantation. The results were published online in the journal The Lancet.

The study is based on a simple idea: to avoid organ rejection after receiving a kidney transplant, many patients need powerful drugs that suppress the immune system (called immunosuppressive drugs). Indeed, some of these powerful agents protect against the rejection, however, damage the transplanted organ they are intended to protect. Long-term studies have shown that this effect decreases the average survival time after transplantation to eight to twelve years. The scientists led by Prof. Klemens Budde and Prof. Petra Reinke, senior physicians at the Medical Department, Division of Nephrology and the Medical Department, Division of Nephrology and Internal Intensive Medicine, Charité pursued, in the ZEUS-study a novel approach, and replaced the damaging immunosuppressive drugs with non-nephrotoxic drugs. "The results move the focus in the treatment of kidney transplant recipients to an improvement of renal function as a marker for long-term survival with a functioning graft," sums up Prof. Budde

The investigation focused on the so-called calcineurin inhibitors such as Cyclosporin A. They are part of regular immunosuppressive protocols after kidney transplantion worldwide and only removed if toxic damage is already apparent in the transplanted kidney. The researchers began 4.5 months after transplantation, with a total of 300 patients aged between 18 and 65, to pursue different treatment strategies. One group continued to receive standard therapy with cyclosporine, in a second group cyclosporine was replaced with another drug. Instead, these patients received the drug everolimus, which has no obvious nephrotoxic effects to the graft.

The final examination twelve months after the transplantation, showed significant benefits for this group: The transplant had clearly better renal function compared to patients on standard therapy with cyclosporine, while the rejection rate rose only slightly. Prof. Budde calls this result "very encouraging ," however he cautions: "This is not proof of the superiority of everolimus. We have to wait for the long-term results of this trial."


Story Source:

The above story is based on materials provided by Charité - Universitätsmedizin Berlin. Note: Materials may be edited for content and length.


Journal Reference:

  1. Klemens Budde, Thomas Becker, Wolfgang Arns, Claudia Sommerer, Petra Reinke, Ute Eisenberger, Stefan Kramer, Wolfgang Fischer, Harald Gschaidmeier, Frank Pietruck. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. The Lancet, 2011; DOI: 10.1016/S0140-6736(10)62318-5

Cite This Page:

Charité - Universitätsmedizin Berlin. "Improved outcomes following kidney transplantation." ScienceDaily. ScienceDaily, 1 March 2011. <www.sciencedaily.com/releases/2011/03/110301091454.htm>.
Charité - Universitätsmedizin Berlin. (2011, March 1). Improved outcomes following kidney transplantation. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2011/03/110301091454.htm
Charité - Universitätsmedizin Berlin. "Improved outcomes following kidney transplantation." ScienceDaily. www.sciencedaily.com/releases/2011/03/110301091454.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) — Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) — A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) — Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) — NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins